Article
Oncology
Chun-Xia He, You Lv, Meng Guo, Huan Zhou, Wei Qin, Dong Zhao, Hui-Jin Li, Lu Xing, Xin Zhou, Peng-Quan Li, Feng Yu, Jian-Hua He, Hui-Ling Cao
Summary: The crystal structure of Hsp90(N)-NVP-AUY922 was successfully determined, confirming the strong binding capability between NVP-AUY922 and Hsp90(N). NVP-AUY922 exhibited inhibitory activity on NSCLC cell line H1299 by inhibiting cell proliferation, inducing cell cycle arrest, and promoting cell apoptosis. The newly designed NVP-AUY922 derivatives showed enhanced binding force with Hsp90(N), which contributes to the development of new anti-NSCLC drugs.
FRONTIERS IN ONCOLOGY
(2022)
Article
Cell Biology
Li Li, Dongming Wu, Shihua Deng, Jin Li, Feng Zhang, Ye Zou, Ting Zhang, Ying Xu
Summary: In this study, NVP-AUY922 was found to significantly improve radiation-induced lung injury by inhibiting the activation of ferroptosis. Mechanistically, NVP-AUY922 alleviated RILI by blocking chaperone-mediated lysosomal degradation of GPX4, providing a potential strategy for the development of novel protective agents against RILI.
CELL DEATH DISCOVERY
(2022)
Article
Oncology
Melissa Schwab, Gabriele Multhoff
Summary: This study investigated the impact of the Hsp90 inhibitor NVP-AUY922 on tumor cells. The results showed that NVP-AUY922 can enhance radiosensitivity in tumor cells, particularly in LDH-/- cells. Impaired lipid metabolism in LDH-/- cells reduces membrane Hsp70 expression, leading to increased radiosensitivity.
FRONTIERS IN ONCOLOGY
(2022)
Article
Cell Biology
Hong Zhang, Fanghui Ge, Xindong Shui, Yuling Xiang, Xinxin Wang, Chang Liao, Jiandong Wang
Summary: High levels of NIX protein contribute to poor prognosis in PCPG patients, while also enhancing antioxidant capacity and reducing stress-induced apoptosis in PC12 cells. Targeting NIX could be a supplemental therapeutic strategy for PCPG with high NIX levels.
CELL STRESS & CHAPERONES
(2021)
Article
Pharmacology & Pharmacy
Pang-Yen Liu, Hsin-Hsueh Shen, Ching-Wen Kung, Shu-Ying Chen, Chia-Hsien Lu, Yen-Mei Lee
Summary: Sepsis is a life-threatening organ dysfunction syndrome caused by bacterial infections, characterized by systemic inflammatory responses and elevated oxidative stress leading to multiple organ dysfunction and disseminated intravascular coagulation. Heat shock protein 70 (HSP70) plays a protective role in cellular homeostasis, while HSP 90 inhibitors have been reported to have anti-inflammatory effects through the induction of HSP70.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Biochemical Research Methods
Sai Kiran Sharma, Jonathan M. Glaser, Kimberly J. Edwards, Elaheh Khozeimeh Sarbisheh, Akam K. Salih, Jason S. Lewis, Eric W. Price
Summary: Synthesizing trastuzumab immunoconjugates with 1-3 DFOs per Ab (T5 and T10) and radiolabeling in low reaction volumes using Chelex treated PBS or HEPEs without a radioprotectant resulted in radioimmunoconjugates with high molar activity/specific activity (97 MBq/nmol; 17.5 +/- 2.2 mCi/mg), preserved immunoreactive fractions (86-93%), and favorable in vivo biodistribution profile with excellent tumor uptake.
BIOCONJUGATE CHEMISTRY
(2021)
Article
Oncology
Rony Mshaik, John Simonet, Aleksandra Georgievski, Layla Jamal, Shaliha Bechoua, Paola Ballerini, Pierre-Simon Bellaye, Zandile Mlamla, Jean-Paul Pais de Barros, Audrey Geissler, Pierre-Jean Francin, Francois Girodon, Carmen Garrido, Ronan Quere
Summary: T-cell and B-cell acute lymphoblastic leukemias are aggressive hematological malignancies that require novel targeted therapies to improve patient outcomes. Research has shown that HSP90 plays a key role in the growth of ALL cells.
BLOOD CANCER JOURNAL
(2021)
Article
Pharmacology & Pharmacy
Minwoo Kang, Jong Il Shin, Sangjin Han, Jung Young Kim, Jeonghoon Park, Kwang Il Kim, Joo Hyun Kang, Tae Sup Lee
Summary: This study evaluated the feasibility of monitoring therapeutic response using Zr-89-DFO-pertuzumab immuno-PET imaging agent for HER2-targeted therapy. The results showed that Zr-89-DFO-pertuzumab can clearly visualize HER2 expressing tumors and demonstrated significant HER2 downregulation in 17-DMAG treated tumors.
Article
Radiology, Nuclear Medicine & Medical Imaging
Melissa A. Lumish, Steven B. Maron, Viktoriya Paroder, Joanne F. Chou, Marinela Capanu, Steven Philemond, Joseph A. O'Donoghue, Heiko Schoder, Jason S. Lewis, Serge K. Lyashchenko, Neeta Pandit-Taskar, Yelena Y. Janjigian
Summary: Variations in HER2 expression between primary tumor and metastases may contribute to drug resistance in HER2+ mEGC. HER2 PET holds promise for noninvasive assessment of HER2 expression and target engagement. This study describes HER2 PET findings in patients with mEGC.
JOURNAL OF NUCLEAR MEDICINE
(2023)
Article
Multidisciplinary Sciences
Danique Giesen, Marjolijn N. Lub-de Hooge, Marcel Nijland, Helen Heyerdahl, Jostein Dahle, Elisabeth G. E. de Vries, Martin Pool
Summary: In this study, [Lu-177]Lu-DOTA-NNV003 was developed as a novel radioimmunotherapy (RIT) for B cell non-Hodgkin's lymphoma (NHL) patients. The use of [Zr-89]Zr-N-sucDf-NNV003 PET imaging accurately predicted the whole-body distribution and tumor uptake of [Lu-177]Lu-DOTA-NNV003. The results showed that [Zr-89]Zr-N-sucDf-NNV003 PET imaging could serve as a useful tool to predict the CD37-targeting effect of [Lu-177]Lu-DOTA-NNV003.
SCIENTIFIC REPORTS
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Sarah R. Verhoeff, Pim P. van de Donk, Erik H. J. G. Aarntzen, Sjoukje F. Oosting, Adrienne H. Brouwers, Iris H. C. Miedema, Jens Voortman, Willemien C. Menke -van der Houven van Oordt, Ronald Boellaard, Dennis Vriens, Marije Slingerland, Rick Hermsen, Ilse van Engen-van Grunsven, Sandra Heskamp, Carla M. L. van Herpen
Summary: In this study, we used 89Zr-DFO-durvalumab PET/CT to predict the treatment response of durvalumab in patients with squamous cell carcinoma of the head and neck. We found that 89Zr-DFO-durvalumab uptake was correlated with tumor PD-L1 expression and 18F-FDG uptake, but it could not predict treatment response.
JOURNAL OF NUCLEAR MEDICINE
(2022)
Article
Immunology
Ander Puyalto, Maria Rodriguez-Remirez, Ines Lopez, Fabiola Iribarren, Jon Ander Simon, Marga Ecay, Maria Collantes, Anna Vilalta-Lacarra, Alejandro Francisco-Cruz, Jose Luis Solorzano, Sergio Sandiego, Ivan Penuelas, Alfonso Calvo, Daniel Ajona, Ignacio Gil-Bazo
Summary: This study demonstrates the use of [Zr-89]-anti-PD-1 immuno-PET as a safe and feasible imaging modality to accurately assess the response to PD-1/PD-L1 blockade in NSCLC.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Oncology
Chenchen Ji, Feng Li, Yang Yuan, Huiqiang Zhang, Li Bian, Shaohua Zhang, Tao Wang, Jianbin Li, Zefei Jiang
Summary: This study compared the efficacy and safety between novel anti-human epidermal growth factor receptor 2 antibody-drug conjugates (ADCs) and trastuzumab emtansine for patients with tyrosine kinase inhibitor (TKI) treatment failure. The results showed that both T-Dxd and other novel anti-HER2 ADCs had significantly better progression-free survival and objective response rate than T-DM1, with tolerable toxicities.
Article
Pharmacology & Pharmacy
Z-W Sun, X-Y Lan, F-L Kong, Y-Y Gao, S. Li, Y-L Xi
Summary: This study found that first-line treatment with docetaxel and bevacizumab with or without trastuzumab for both HER2-positive and HER2-negative metastatic breast cancer patients resulted in longer survival, particularly in terms of progression-free survival. Although the overall response rates were also significantly improved, there is still controversy based on the current evidence.
EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES
(2021)
Article
Medicine, Research & Experimental
Johannes Schwenck, Dominik Sonanini, Dominik Seyfried, Walter Ehrlichmann, Gabriele Kienzle, Gerald Reischl, Pascal Krezer, Ian Wilson, Ron Korn, Irene Gonzalez-Menendez, Leticia Quintanilla-Martinez, Ferdinand Seith, Andrea Forschner, Thomas Eigentler, Lars Zender, Martin Roecken, Bernd J. Pichler, Lukas Flatz, Manfred Kneilling, Christian la Fougere
Summary: This study investigated the feasibility of [Zr-89]Zr-Df-IAB22M2C positron emission tomography/magnetic resonance imaging (PET/MRI) in assessing the distribution of CD8(+) T cells in metastatic cancer patients. The results showed that only two out of eight patients undergoing immune checkpoint inhibitor therapy (ICT) exhibited increased tracer uptake in their metastatic lesions. Additionally, high uptake was observed in lymph nodes and bone marrow. We hypothesize that alterations in [Zr-89]Zr-Df-IAB22M2C uptake in lymphoid organs may be associated with the response to ICT.
Article
Oncology
Lalitha K. Shankar, Erich Huang, Saskia Litiere, Otto S. Hoekstra, Larry Schwartz, Sandra Collette, Ronald Boellaard, Jan Bogaerts, Lesley Seymour, Elisabeth G. E. deVries
Summary: Currently, guidelines for PET with FDG-PET interpretation for therapy response in oncology involve visual evaluation of FDG-PET/CT scans. However, quantitative measurements of metabolic activity in tumors may be more useful. Guidelines based on such measurements have been proposed, but more analysis is needed for regular use.
CLINICAL CANCER RESEARCH
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Joyce van Sluis, Walter Noordzij, Elisabeth G. E. de Vries, Iris C. Kok, Derk Jan A. de Groot, Mathilde Jalving, Marjolijn N. Lub-de Hooge, Adrienne H. Brouwers, Ronald Boellaard
Summary: This study explores the influence of using manual segmentations versus an AI-based automated segmentation tool on calculating whole-body effective doses. The results show that using AI-based segmentations can save time and achieve higher similarity coefficients compared to manual segmentations. The whole-body effective doses show minimal differences for the six patients.
MOLECULAR IMAGING AND BIOLOGY
(2023)
Article
Oncology
Sarah Halford, Gareth J. Veal, Stephen R. Wedge, Geoffrey S. Payne, Chris M. Bacon, Philip Sloan, Ilaria Dragoni, Kathrin Heinzmann, Sarah Potter, Becky M. Salisbury, Maxime Chenard-Poirier, Alastair Greystoke, Elizabeth C. Howell, William A. Innes, Karen Morris, Chris Plummer, Mihaela Rata, George Petrides, Hector C. Keun, Udai Banerji, Ruth Plummer
Summary: The purpose of this study is to investigate the effects of inhibiting lactate transport via monocarboxylate transporter 1 (MCT1) on tumor cells. The results from the dose-escalation part of the study showed that AZD3965, a first-in-class MCT1 inhibitor, is well tolerated at doses that produce target engagement.
CLINICAL CANCER RESEARCH
(2023)
Article
Oncology
Robert Jones, Ruth Plummer, Victor Moreno, Louise Carter, Desamparados Roda, Elena Garralda, Rebecca Kristeleit, Debashis Sarker, Tobias Arkenau, Patricia Roxburgh, Harriet S. Walter, Sarah Blagden, Alan Anthoney, Barbara J. Klencke, Mark M. Kowalski, Udai Banerji
Summary: The purpose of this study was to assess the safety, recommended dose, pharmacokinetic profile, and clinical activity of the novel checkpoint kinase 1 (Chk1) inhibitor SRA737 in combination with gemcitabine in patients with advanced solid tumors. The results showed that the combination of SRA737 and low-dose gemcitabine was well tolerated and demonstrated tumor responses in anogenital cancer and other solid tumors.
CLINICAL CANCER RESEARCH
(2023)
Article
Oncology
Sarah R. Verhoeff, Sjoukje F. Oosting, Sjoerd G. Elias, Suzanne C. van Es, Sophie L. Gerritse, Lindsay Angus, Sandra Heskamp, Ingrid M. E. Desar, C. Willemien Menke-van der Houven van Oordt, Astrid A. M. van der Veldt, Anne I. J. Arens, Adrienne H. Brouwers, Bertha Eisses, Peter F. A. Mulders, Otto S. Hoekstra, Gerben J. C. Zwezerijnen, Winette T. A. van der Graaf, Erik H. J. G. Aarntzen, Wim J. G. Oyen, Carla M. L. van Herpen
Summary: Patients with metastatic clear-cell renal cell carcinoma (mccRCC) with good or intermediate prognosis can consider watchful waiting (WW), especially those who meet the watch and wait (W&W) criteria of < 2 International Metastatic RCC Database Consortium criteria and <=2 metastatic sites. This study aimed to assess the predictive value of [F-18]FDG PET/CT and [Zr-89]Zr-DFO-girentuximab PET/CT for the duration of WW in patients with mccRCC.
CLINICAL CANCER RESEARCH
(2023)
Article
Oncology
Ramsha Iqbal, Maqsood Yaqub, Huseyyin O. Bektas, Daniela E. Oprea-Lager, Elisabeth G. E. de Vries, Andor W. J. M. Glaudemans, Philippe Aftimos, Geraldine Gebhart, Andrew P. Beelen, Robert C. Schuit, Albert D. Windhorst, Ronald Boellaard, C. Willemien Menke-van der Houven van Oordt
Summary: The purpose of this study was to investigate the use of [18F]-fluorodeoxyglucose ([18F]FDG) and [18F]-fluoro-17(3-estradiol ([18F]FES) PET/CT imaging in patients with metastatic ER-positive breast cancer undergoing treatment with rintodestrant. The study found that absence of ER expression on [18F]FES PET is a predictor for no response to rintodestrant. [18F]FES uptake during treatment and at time of progression is useful to monitor the effect of therapy and continued mode of action of SERDs.
CLINICAL CANCER RESEARCH
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Milou E. Noltes, Maximilian Bader, Madelon J. H. Metman, Jasper Vonk, Pieter J. Steinkamp, Jan Kukacka, Henriette E. Westerlaan, Rudi A. J. O. Dierckx, Bettien M. van Hemel, Adrienne H. Brouwers, Gooitzen M. van Dam, Dominik Juestel, Vasilis Ntziachristos, Schelto Kruijff
Summary: This study examines the potential of multispectral optoacoustic tomography (MSOT) for risk stratification of thyroid nodules. The findings show a correlation between vascular patterns and thyroid malignancy, and identify malignant features in MSOT images that are verified by histopathology. However, mean oxygen saturation does not provide significant differences between benign and malignant thyroid nodules. Recommendations are made to consider optoacoustic features and chromophore quantification together for malignancy risk assessment.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Joyce van Sluis, Ronald Boellaard, Rudi A. J. O. Dierckx, Evelien L. M. van Esch, Demi A. Croes, Laura Kist de Ruijter, Pim P. van de Donk, Elisabeth G. E. de Vries, Walter Noordzij, Adrienne H. Brouwers
Summary: ImmunoPET imaging is a non-invasive method to characterize tumor lesions and evaluate treatment response. The use of SiPM-based PET/CT systems can improve the sensitivity of Zr-89 immunoPET imaging. The scan duration using the Vision can be reduced up to 50% while maintaining image quality using the EARL1 compliant reconstruction protocol.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2023)
Editorial Material
Multidisciplinary Sciences
Elena Garralda, Scott A. Laurie, Lesley Seymour, Elisabeth G. E. de Vries
Summary: Early detection of immunotherapy-induced tumor response is crucial, but therapy-induced pseudoprogression can make it complicated. A consensus guideline called iRECIST, a modification of RECIST version 1.1, was developed. This article explores the next steps required to test its validity and proposes novel approaches for response criteria.
NATURE COMMUNICATIONS
(2023)
Article
Oncology
Elisabeth G. E. de Vries, Josef Rueschoff, Martijn Lolkema, Josep Tabernero, Luca Gianni, Emile Voest, Derk Jan A. de Groot, Daniel Castellano, Gilles Erb, Julia Naab, Margarita Donica, Regula Deurloo, Michiel S. van Der Heijden, Giuseppe Viale
Summary: This study aimed to investigate tumor HER2 expression and its effects on T-DM1 treatment in patients with HER2-positive urothelial bladder cancer or pancreatic cancer/cholangiocarcinoma. The results showed that some HER2-positive bladder cancer and pancreatic cancer patients responded well to T-DM1, and it also provided insight into the prevalence of HER2 positivity and expression patterns in these three non-breast tumor types.
Review
Oncology
Alvaro H. Ingles Garces, Nuria Porta, Trevor A. Graham, Udai Banerji
Summary: The evolution of drug-resistant cell subpopulations leads to treatment failure in cancer. Preclinical evidence suggests the possibility of influencing the response to subsequent treatments by modeling clonal evolution and collateral sensitivity. New therapy strategies and clinical trial designs are needed to steer cancer evolution. The competition between different subsets of drug-sensitive and resistant clones for nutrients/blood supply indicates the potential use of treatment paradigms based on cell-cell competition. This requires different clinical trial designs from the conventional practice and the integration of next-generation sequencing to improve the assessment of clinical response/resistance and exploit evolution.
CANCER TREATMENT REVIEWS
(2023)
Article
Multidisciplinary Sciences
James Spicer, Bristi Basu, Ana Montes, Udai Banerji, Rebecca Kristeleit, Rowan Miller, Gareth J. J. Veal, Christopher J. J. Corrigan, Stephen J. J. Till, Mariangela Figini, Silvana Canevari, Claire Barton, Paul Jones, Sarah Mellor, Simon Carroll, Chris Selkirk, George Nintos, Vineet Kwatra, Ionut-Gabriel Funingana, Gary Doherty, Hannah J. J. Gould, Giulia Pellizzari, Mano Nakamura, Kristina M. M. Ilieva, Atousa Khiabany, Chara Stavraka, Jitesh Chauhan, Cheryl Gillett, Sarah Pinder, Heather J. J. Bax, Debra H. H. Josephs, Sophia N. N. Karagiannis
Summary: The study reports the results of a phase I dose escalation trial of MOv18 IgE, a chimeric first-in-class IgE antibody, in patients with tumours expressing folate receptor-alpha. The most common toxicity observed was transient urticaria and evidence of anti-tumour activity was observed in a patient with ovarian cancer.
NATURE COMMUNICATIONS
(2023)
Review
Oncology
Mostafa Roya, Samaneh Mostafapour, Philipp Mohr, Laura Providencia, Zekai Li, Johannes H. van Snick, Adrienne H. Brouwers, Walter Noordzij, Antoon T. M. Willemsen, Rudi A. J. O. Dierckx, Adriaan A. Lammertsma, Andor W. J. M. Glaudemans, Charalampos Tsoumpas, Riemer H. J. A. Slart, Joyce van Sluis
Summary: Recently, a new type of PET scanner with long axial field-of-view (LAFOV) has been introduced in clinical practice. Compared to conventional PET scanners, LAFOV scanners have a larger coverage and higher sensitivity, providing new opportunities for clinical applications, such as reducing scan time, decreasing the amount of radiotracer used, and using dynamic or parametric imaging. Emerging technologies like artificial intelligence and imaging with multiple radiotracers can further enhance the clinical application of LAFOV PET.
Article
Oncology
Subramanian Venkatesan, Mihaela Angelova, Jirina Bartkova, Samuel F. Bakhoum, Jiri Bartek, Nnennaya Kanu, Charles Swanton
Summary: Our recent study found that APOBEC3B is upregulated in the preinvasive stages of non-small cell lung cancer and breast cancer. We suggest that APOBEC3 promotes copy number intratumor heterogeneity prior to invasion, thereby providing a substrate for cancer evolution.
MOLECULAR & CELLULAR ONCOLOGY
(2023)